Nordic Capital has signed an agreement to acquire a majority share in IntegriChain, a leading provider of pharmaceutical technology, data, consulting, and outsourcing solutions designed to improve how life sciences products reach customers. IntegriChain delivers pharma’s only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy. Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
IntegriChain’s integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability. ICyte enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net.
“IntegriChain has established a significant position over the last 17 years as a leader in access and commercialization for life sciences – helping manufacturers of all size from strategy to operational execution. We are confident that the company will continue its already strong record of growth by helping customers address their most pressing market access challenges as the industry evolves. The fact that IntegriChain supports more than 400 pharmaceutical customers speaks to the quality of the platform, data, and services they provide. We’re certain that Nordic Capital’s experience supporting companies with similar ambitions, our extensive industry networks, and deep-sector knowledge will take the company to even greater heights,” said Daniel Berglund, Co-Head of Healthcare, Nordic Capital Investment Advisors.
Josh Halpern, Co-Founder and CEO of IntegriChain, said: “We’re pleased to have Nordic Capital as a new partner to support us on our journey. We are immensely proud of the team at IntegriChain and how we help pharma manufacturers deliver winning commercialization strategies while optimizing their net revenue. With Nordic Capital’s invaluable healthcare and technology experience and expertise, I’m confident that this partnership will enable us to extend our position as a leading platform for pharma manufacturers to bring their science to market. We thank Accel-KKR for their many years of sound guidance and support to help us ready IntegriChain for this important next phase of our business development.”
The terms of the transaction were not disclosed. Completion of the transaction is expected before year end and is subject to customary closing conditions, including relevant regulatory approvals.
Morgan Stanley & Co. LLC and Harris Williams LLC are acting as financial advisors to IntegriChain.
Evercore is acting as financial advisor to Nordic Capital.
